Targeting platelet GPVI with glenzocimab: a novel mechanism for inhibition
暂无分享,去创建一个
S. Watson | M. Pugnière | M. Jandrot-Perrus | M. Welin | P. Billiald | Alexandre Slater | I. Jiacomini | Déborah François | Kristell Lebozec | Joanne C. Clark | Loyau Stéphane | Nadia Rose | Elie Toledano
[1] S. Watson,et al. Evidence that GPVI is Expressed as a Mixture of Monomers and Dimers, and that the D2 Domain is not Essential for GPVI Activation , 2021, Thrombosis and Haemostasis.
[2] M. Jandrot-Perrus,et al. Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks , 2017, mAbs.
[3] K. Horii,et al. Structural basis for platelet collagen responses by the immune-type receptor glycoprotein VI. , 2006, Blood.
[4] J. Lacapère,et al. Identification of Residues within Human Glycoprotein VI Involved in the Binding to Collagen , 2004, Journal of Biological Chemistry.
[5] M. Jandrot-Perrus,et al. Fibrinogen Bondy: a new case of dysfibrinogenemia. Isolation of the abnormal fibrinogen molecules. , 1982, Thrombosis research.